Otsuka Pharmaceutical News
Most Popular Otsuka Pharmaceutical Story
Bristol pays $400M for Abilify lifeline
Few drugmakers are expected to have a year as tough as Bristol-Myers Squibb's 2012. Like the Mayan calendar, time would run out in 2012 on two of Bristol's blockbuster meds: Plavix and Abilify. And... Read more...
Latest Headlines
- November 20, 2009
- November 5, 2009
- April 6, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
